These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 12631589

  • 1. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J.
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 3. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.
    Clin Cancer Res; 2005 May 01; 11(9):3315-9. PubMed ID: 15867229
    [Abstract] [Full Text] [Related]

  • 4. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M, Hacène K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F.
    Clin Cancer Res; 2000 Dec 01; 6(12):4745-54. PubMed ID: 11156229
    [Abstract] [Full Text] [Related]

  • 5. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.
    Mod Pathol; 2002 Aug 01; 15(8):853-61. PubMed ID: 12181271
    [Abstract] [Full Text] [Related]

  • 6. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
    Park YH, Kim ST, Cho EY, Choi YL, Ok ON, Baek HJ, Lee JE, Nam SJ, Yang JH, Park W, Choi DH, Huh SJ, Ahn JS, Im YH.
    Breast Cancer Res Treat; 2010 Feb 01; 119(3):653-61. PubMed ID: 19957028
    [Abstract] [Full Text] [Related]

  • 7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Feb 01; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 8. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
    Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H.
    Clin Cancer Res; 2005 Jun 15; 11(12):4372-81. PubMed ID: 15958620
    [Abstract] [Full Text] [Related]

  • 9. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J, Lang RG, Fan Y, Fu L.
    Zhonghua Zhong Liu Za Zhi; 2007 Apr 15; 29(4):284-8. PubMed ID: 17760256
    [Abstract] [Full Text] [Related]

  • 10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 15; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 11. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Jul 15; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
    Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8623-31. PubMed ID: 16361546
    [Abstract] [Full Text] [Related]

  • 19. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
    Liu S, Edgerton SM, Moore DH, Thor AD.
    Clin Cancer Res; 2001 Jun 15; 7(6):1716-23. PubMed ID: 11410511
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.